Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity

Cancer Gene Therapy

Volumn 20, Issue 1, 2013, Pages 46-56

  Yuan, Z ^a   Syrkin, G ^a   Adem, A ^a   Geha, R ^a   Pastoriza, J ^a   Vrikshajanani, C ^a   Smith, T ^b   Quinn, T J ^a   Alemu, G ^a   Cho, H ^a   Barrett, C J ^a   Arap, W ^b   Pasqualini, R ^b   Libutti, S K ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adeno associated virus bacteriophage tumor necrosis factor a (AAVP TNF a); Apoptosis; Conventional chemotherapy; LCL161; Targeted gene therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; INHIBITOR OF APOPTOSIS PROTEIN; LCL 161; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MELANOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE THERAPY;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DEPENDOVIRUS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC THERAPY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MELANOMA; MICE; MICE, NUDE; ORGAN SPECIFICITY; PROTEOLYSIS; THIAZOLES; TRANSDUCTION, GENETIC; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENO-ASSOCIATED VIRUS; INTRACISTERNAL A-PARTICLES; MUS; MUS MUSCULUS;

EID: 84871973263     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.83     Document Type: Article

References (46)

1. Larocca D, Kassner PD, Witte A, Ladner RC, Pierce GF, Baird A. Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage. FASEB J 1999; 13: 727-734.
2. Barrow PA, Soothill JS. Bacteriophage therapy and prophylaxis: Rediscovery and renewed assessment of potential. Trends Microbiol 1997; 5: 268-271.
3. Ivanenkov V, Felici F, Menon AG. Uptake and intracellular fate of phage display vectors in mammalian cells. Biochim Biophys Acta 1999; 1448: 450-462.
4. Weber-Dabrowska B, Mulczyk M, Gorski A. Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. Transplant Proc 2003; 35: 1385-1386.
5. Borysowski J, Gorski A. Is phage therapy acceptable in the immunocompromised host? Int J Infect Dis 2008; 12: 466-471.
6. Bartlett DL, Buell JF, Libutti SK, Reed E, Lee KB, Figg WD et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 1998; 83: 1251-1261.
7. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 2001; 129: 176-187.
8. Alexander Jr. HR, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998; 16: 1479-1489.
9. Alexander Jr. HR, Bartlett DL, Libutti SK. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist 2000; 5: 416-424.
10. Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2000; 6: 3062-3070.
11. Alexander Jr. HR, Libutti SK, Bartlett DL, Pingpank JF, Kranda K, Helsabeck C et al. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. Cancer 2002; 95: 730-736.
12. Libutti SK, Barlett DL, Fraker DL, Alexander HR. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg 2000; 191: 519-530.
13. Lans TE, Bartlett DL, Libutti SK, Gnant MF, Liewehr DJ, Venzon DJ et al. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion. Clin Cancer Res 2001; 7: 784-790.
14. Lejeune FJ, Lienard D, Matter M, Ruegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 2006; 6: 6.
15. Rivera F, Lopez-Tarruella S, Vega-Villegas ME, Salcedo M. Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev 2009; 35: 335-339.
16. Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, Marini 3rd FC et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 2006; 125: 385-398.
17. Hajitou A, Rangel R, Trepel M, Soghomonyan S, Gelovani JG, Alauddin MM et al. Design and construction of targeted AAVP vectors for mammalian cell transduction. Nat Protoc 2007; 2: 523-531.
18. Pasqualini R, Koivunen E, Ruoslahti E. A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J Cell Biol 1995; 130: 1189-1196.
19. Tandle A, Hanna E, Lorang D, Hajitou A, Moya CA, Pasqualini R et al. Tumor vasculature-targeted delivery of tumor necrosis factor-alpha. Cancer 2009; 115: 128-139.
20. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A et al. Launching a novel preclinical infrastructure: Comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One 2009; 4: E4972.
21. Gyrd-Hansen M, Meier P. IAPs: From caspase inhibitors to modulators of NFkappaB, inflammation and cancer. Nat Rev Cancer 2010; 10: 561-574.
22. Gray D, McKenzie MD, Nachbur U, Huang DC, Bouillet P, Thomas HE et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 2009; 460: 1035-1039.
23. Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000; 408: 1008-1012.
24. Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 2001; 410: 112-116.
25. Chen KF, Lin JP, Shiau CW, Tai WT, Liu CY, Yu HC et al. Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. Biochem Pharmacol 2012; 84: 268-277.
26. Kurbanov BM, Fecker LF, Geilen CC, Sterry W, Eberle J. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene 2007; 26: 3364-3377.
27. Gaither A, Porter D, Yao Y, Borawski J, Yang G, Donovan J et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res 2007; 67: 11493-11498.
28. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem 2008; 283: 24295-24299.
29. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA 2008; 105: 11778-11783.
30. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700.
31. Ashkenazi A, Herbst RS. To kill a tumor cell: The potential of proapoptotic receptor agonists. J Clin Invest 2008; 118: 1979-1990.
32. Newsom-Davis T, Prieske S, Walczak H. Is TRAIL the holy grail of cancer therapy? Apoptosis 2009; 14: 607-623.
33. Damaraju VL, Bouffard DY, Wong CK, Clarke ML, Mackey JR, Leblond L et al. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer. BMC Cancer 2007; 7: 121.
34. Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S et al. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 2009; 69: 5876-5884.
35. Firestone B, Conway C, Yang G, Gao H, Porter D, Slisz J et al. Correlation between TNFa and LCL161 anti-tumor activity in patient derived xenograft models of human cancer. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics-Nov 15-19; Boston, MA 2009.
36. Friedl J, Puhlmann M, Bartlett DL, Libutti SK, Turner EN, Gnant MF et al. Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: Relationship between the procoagulant and permeability effects of TNF. Blood 2002; 100: 1334-1339.
37. Kerkar S, Williams M, Blocksom JM, Wilson RF, Tyburski JG, Steffes CP. TNF-alpha and IL-1beta increase pericyte/endothelial cell co-culture permeability. J Surg Res 2006; 132: 40-45.
38. Eschenburg G, Eggert A, Schramm A, Lode HN, Hundsdoerfer P. Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF-a-independent apoptosis. Cancer Res 2012; 72: 2645-2656.
39. Brouckaert PG, Everaerdt B, Libert C, Takahashi N, Fiers W. Species specificity and involvement of other cytokines in endotoxic shock action of recombinant tumour necrosis factor in mice. Agents Actions 1989; 26: 196-198.
40. Fransen L, Ruysschaert MR, Van der Heyden J, Fiers W. Recombinant tumor necrosis factor: Species specificity for a variety of human and murine transformed cell lines. Cell Immunol 1986; 100: 260-267.
41. Kramer SM, Aggarwal BB, Eessalu TE, McCabe SM, Ferraiolo BL, Figari IS et al. Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha. Cancer Res 1988; 48: 920-925.
42. Xu L, Pirollo KF, Chang EH. Tumor-targeted P53-gene therapy enhances efficacy of conventional chemeotherapy. J Control Release 2001; 74: 115-128.
43. Li M, Xu T, Zhang Z, Xue X, Zhang C, Qin X et al. A Phase II multicenter, randomized, double-blind study of a recombinant mutated human tumor necrosis factor-alpha in combination with chemotherapies in cancer patients. Cancer Sci 2012; 103: 288-295.
44. Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S et al. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol Cancer Ther 2011; 10: 902-914.
45. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M et al. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 2011; 43: 449-463.
46. Haas TL, Emmerich CH, Gerlach B. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell 2009; 36: 831-844.